The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models

被引：3
|
作者：
Song, Kyung W.
Edgar, Kyle A.
Kirkpatrick, Donald S.
Phu, Lilian
Schmidt, Stephen
Nannini, Michelle
Hong, Rebecca
Cheng, Eric
Crocker, Lisa
Young, Amy
Sampath, Deepak
Friedman, Lori
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway
    Guan, Ruijuan
    Kang, Zefeng
    Li, Ling
    Yan, Xin
    Gao, Tianpeng
    PLOS ONE, 2024, 19 (01):
  • [42] Selective PI3K inhibition in wild type and PIK3CA mutated human gastrointestinal cancer
    Mueller, A.
    Bachmann, E.
    Linnig, M.
    Khillimberger, K.
    Galle, P. R.
    Moehler, M.
    ONKOLOGIE, 2011, 34 : 246 - 246
  • [43] PIK3CA C2 domain deletions hyperactivate PI3K, generate oncogene dependence and are exquisitely sensitive to PI3Kα inhibitors
    Croessmann, Sarah
    Sheehan, Jonathan
    Sliwoski, Gregory
    Leelatian, Nalin
    He, Jie
    Nagy, Rebecca
    Balko, Justin M.
    Mayer, Ingrid A.
    Lanman, Richard B.
    Miller, Vincent
    Cantley, Lewis C.
    Irish, Jonathan M.
    Meiler, Jens
    Arteaga, Carlos L.
    CANCER RESEARCH, 2017, 77
  • [44] Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
    Wang, Shu
    Liu, Mingyue
    Lian, Siheng
    Liu, Naiming
    Zhang, Guibin
    Zhao, Qingchun
    Zhang, Yingshi
    Jian, Lingyan
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [45] MEK and PI3K signaling cooperate through mTORC1/2 to promote PIK3CA mutant melanoma cell proliferation
    Silva, Jillian M.
    Deuker, Marian M.
    Baguley, Bruce C.
    McMahon, Martin
    CANCER RESEARCH, 2016, 76
  • [46] In silico approach to target PI3K/Akt/mTOR axis by selected Olea europaea phenols in PIK3CA mutant colorectal cancer
    Sain, Arindam
    Kandasamy, Thirukumaran
    Naskar, Debdut
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (21): : 10962 - 10977
  • [47] Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers
    Barlaam, Bernard
    Cosulich, Sabina
    Delouvrie, Benedicte
    Fitzek, Martina
    Germain, Herve
    Green, Stephen
    Harris, Craig S.
    Hudson, Kevin
    Lambert-van der Brempt, Christine
    Lamorlette, Maryannick
    Antoine, Le Griffon
    Morgentin, Remy
    Ouvry, Gilles
    Page, Ken
    Pasquet, Georges
    Ruston, Linette
    Saleh, Twana
    Vautier, Michel
    Ward, Lara
    CANCER RESEARCH, 2015, 75
  • [48] Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC
    Moore, Gillian
    Elbai, Samira
    Heavey, Susan
    Finn, Stephen
    O'Neill, Michael
    Gately, Kathy
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 48 - 48
  • [49] Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer
    Kim, Areumnuri
    Lee, Jung-Eun
    Lee, Seung-Sook
    Kim, Cherin
    Lee, Sun-Joo
    Jang, Won-Suk
    Park, Sunhoo
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (04) : 984 - 996
  • [50] Mutational status of PIK3ca oncogene in oral cancer-In the new age of PI3K inhibitors
    Denninghoff, V
    Muino, A.
    Diaz, M.
    Harada, L.
    Lence, A.
    Turon, P.
    Labbrozzi, M.
    Aguas, S.
    Penaloza, P.
    Avagnina, A.
    Adler, I
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (01)
12345